Urologic Oncology: Seminars and Original Investigations
Volume 27, Issue 3, May–June 2009, Pages 236-237
Translational studies in urologic oncologyHypoxia inducible factor (HIF): Its central role in renal cell cancer targeted therapy
References (6)
Sorafenib: Scientific rationale for single-agent and combination therapy in clear-cell renal cell carcinoma
Clin Genitourinary Cancer
(2005)- et al.
Case 17-2008: A 63 year-old man with metastatic renal-cell carcinoma
New Eng J Med
(2008) - et al.
Mutation of the VHL tumor suppressor gene in renal carcinoma
Nat Genet
(1994)
There are more references available in the full text version of this article.
Cited by (4)
A NIR turn-on fluorescent probe applied in cytochrome P450 reductase detection and hypoxia imaging in tumor cells
2017, Dyes and PigmentsCitation Excerpt :The tumor oxygenation status tampers the therapeutic effects of radiotherapy, chemotherapy, biotherapy and thermotherapy [1,2]. Tumor hypoxic cells not only show low sensitivity to radiotherapy, but also resist to chemotherapy and biotherapy [3,4]. Detection of hypoxia is helpful for the establishment of clinical therapeutic plan and the patient-oriented individual therapeutic plan [5].
JAK3 in clear cell renal cell carcinoma: Mutational screening and clinical implications
2013, Urologic Oncology: Seminars and Original InvestigationsCitation Excerpt :During the past years, knowledge on pathways in clear cell renal cell carcinoma (ccRCC) has improved significantly [1–5].
Discovery of Cycloalkyl[c]thiophenes as Novel Scaffolds for Hypoxia-Inducible Factor-2α Inhibitors
2023, Journal of Medicinal ChemistryModulating Hypoxia via Nanomaterials Chemistry for Efficient Treatment of Solid Tumors
2018, Accounts of Chemical Research
Copyright © 2009 Elsevier Inc. All rights reserved.